HeartBeam (NASDAQ:BEAT) Director Marga Ortigas-Wedekind Purchases 25,000 Shares of Stock

HeartBeam, Inc. (NASDAQ:BEAT) Director Marga Ortigas-Wedekind bought 25,000 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were acquired at an average price of $0.80 per share, for a total transaction of $20,000.00. Following the acquisition, the director directly owned 137,293 shares of the company’s stock, valued at approximately $109,834.40. The trade was a 22.26% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

HeartBeam Stock Down 8.5%

HeartBeam stock opened at $0.81 on Friday. The stock has a 50-day simple moving average of $1.30 and a 200 day simple moving average of $1.62. The stock has a market capitalization of $33.28 million, a price-to-earnings ratio of -1.31 and a beta of -0.63. HeartBeam, Inc. has a 12-month low of $0.54 and a 12-month high of $4.00.

HeartBeam (NASDAQ:BEAT) last issued its quarterly earnings data on Thursday, March 12th. The medical research company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. B. Riley Financial began coverage on shares of HeartBeam in a report on Tuesday, March 31st. They issued a “buy” rating and a $4.00 price target for the company. D. Boral Capital initiated coverage on HeartBeam in a report on Friday, March 27th. They set a “buy” rating and a $5.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartBeam in a research note on Monday, December 29th. Wall Street Zen lowered HeartBeam to a “strong sell” rating in a research note on Saturday, January 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.50 price target on shares of HeartBeam in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $4.80.

Hedge Funds Weigh In On HeartBeam

A number of large investors have recently bought and sold shares of the company. Ritholtz Wealth Management lifted its position in shares of HeartBeam by 49.6% in the fourth quarter. Ritholtz Wealth Management now owns 208,191 shares of the medical research company’s stock worth $500,000 after purchasing an additional 69,009 shares in the last quarter. Raymond James Financial Inc. grew its stake in HeartBeam by 212.5% in the third quarter. Raymond James Financial Inc. now owns 88,050 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 59,872 shares in the last quarter. State Street Corp raised its stake in shares of HeartBeam by 60.1% during the 4th quarter. State Street Corp now owns 125,473 shares of the medical research company’s stock worth $301,000 after purchasing an additional 47,100 shares in the last quarter. Kestra Private Wealth Services LLC boosted its holdings in shares of HeartBeam by 23.4% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 175,989 shares of the medical research company’s stock valued at $290,000 after buying an additional 33,344 shares during the last quarter. Finally, Insigneo Advisory Services LLC bought a new position in shares of HeartBeam in the fourth quarter valued at $74,000. Institutional investors and hedge funds own 7.77% of the company’s stock.

HeartBeam News Summary

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: Senior insiders (multiple directors and the CFO) purchased a total of ~1.12M shares at $0.80 apiece (roughly $895k in aggregate), including a 750k‑share buy by director Mark E. Strome, signaling management confidence and increasing insider ownership. SEC Filing — Mark E. Strome
• Positive Sentiment: Reported short interest fell ~22.8%, which reduces immediate short‑selling pressure and can support the share price during this post‑offering period. Short interest report
• Neutral Sentiment: Recent analyst/press comparison pieces examine HeartBeam versus peers; useful for longer‑term competitive/contextual perspective but not an immediate catalyst. Competitive comparison
• Negative Sentiment: HeartBeam launched and priced a $10 million public offering to support commercialization and AI initiatives. Equity offerings are dilutive and typically weigh on the share price; media coverage noted the stock slipped after the offering was priced. Offering pricing Offering closing Market reaction article

HeartBeam Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.